Julia Maria Ressler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Maria Ressler has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Hoeller
Department of Dermatology, Medical University of Vienna, Vienna, Austria
6 shared publications - Nina Zila
Department of Dermatology, Medical University of Vienna, Vienna, Austria
4 shared publications - Reinhard Dummer
Department of Dermatology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland
3 shared publications - Alexander Springer
Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria
2 shared publications Arkadiusz Nawrocki
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
2 shared publications- Christian Posch
Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, 81675 Munich, Germany
2 shared publications
Latest Publications
- Open Access
The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis
Background: Adjuvant radiotherapy (RT) may improve in-field regional tumor control in melanoma following resection of lymph node macrometastases. However, no significant effect on recurrence-free survival or overall survival has been demonstrated. The approval of adjuvant systemic immune checkpoint inhibitors and targeted therapies has significantly impacted the role of adjuvant RT. Its use in clinical practice has decreased, with heterogeneous treatment indications and approaches observed across institutions and regions. Objectives: The aim of the present study was to characterize the population of melanoma patients still undergoing adjuvant RT in the era of modern adjuvant systemic treatments, and to outline potential clinical scenarios in which it may continue to play a role in the future. Patients and methods: Fifty-eight patients treated with adjuvant RT were identified in five participating Austrian and Swiss dermato-oncologic centers. Treatment timing, toxicity, recurrence patterns, and survival outcomes were analyzed, and compared to 88 stage-matched, non-irradiated patients from a German cohort of patients who met formal RT criteria. Results: The majority of irradiated patients (53.5%) received RT before systemic therapy. The concurrent administration of adjuvant systemic therapy and radiotherapy did not increase the frequency of RT-associated toxicities (77.8% vs. 74.2%, p = 0.456). No significant differences in recurrence-free survival or overall survival were observed between irradiated and non-irradiated patients (p = 0.725 and p = 0.986, respectively). Conclusions: Although still recommended in certain melanoma guidelines, adjuvant RT is infrequently performed in the era of modern systemic treatments. Due to its exclusively locoregional efficacy, the application of adjuvant RT should be limited to clearly defined scenarios where systemic treatment options are limited and locoregional control is most important. The concurrent administration of adjuvant RT and systemic therapy is safe and should be preferred if a combined treatment strategy is chosen.
Open AccessThe Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis
Background: Adjuvant radiotherapy (RT) may improve in-field regional tumor control in melanoma following resection of lymph node macrometastases. However, no significant effect on recurrence-free survival or overall survival has been demonstrated. The approval of adjuvant systemic immune checkpoint inhibitors and targeted therapies has significantly impacted the role of adjuvant RT. Its use in clinical practice has decreased, with heterogeneous treatment indications and approaches observed across institutions and regions. Objectives: The aim of the present study was to characterize the population of melanoma patients still undergoing adjuvant RT in the era of modern adjuvant systemic treatments, and to outline potential clinical scenarios in which it may continue to play a role in the future. Patients and methods: Fifty-eight patients treated with adjuvant RT were identified in five participating Austrian and Swiss dermato-oncologic centers. Treatment timing, toxicity, recurrence patterns, and survival outcomes were analyzed, and compared to 88 stage-matched, non-irradiated patients from a German cohort of patients who met formal RT criteria. Results: The majority of irradiated patients (53.5%) received RT before systemic therapy. The concurrent administration of adjuvant systemic therapy and radiotherapy did not increase the frequency of RT-associated toxicities (77.8% vs. 74.2%, p = 0.456). No significant differences in recurrence-free survival or overall survival were observed between irradiated and non-irradiated patients (p = 0.725 and p = 0.986, respectively). Conclusions: Although still recommended in certain melanoma guidelines, adjuvant RT is infrequently performed in the era of modern systemic treatments. Due to its exclusively locoregional efficacy, the application of adjuvant RT should be limited to clearly defined scenarios where systemic treatment options are limited and locoregional control is most important. The concurrent administration of adjuvant RT and systemic therapy is safe and should be preferred if a combined treatment strategy is chosen.
- Open Access
- 2 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70652
Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs). Here, we retrospectively characterized severe n‐irAEs in a monocentric cohort. Methods: We screened an in‐house registry of the Medical University of Vienna, Austria, including all patients treated with ICIs between 2007 and 2023. Patients who underwent a neurological evaluation were identified, and their medical records were reviewed. Cases with severe (i.e., grade ≥ 3) n‐irAEs were analyzed. We report clinical and demographic characteristics, neurological manifestations, treatment and outcomes. Results: Ten out of 2043 screened patients (i.e., 0.5%) developed severe n‐irAEs. In most cases ( n = 7), neurological manifestations involved the neuromuscular system and/or peripheral nerves, including myasthenia/myositis ( n = 5), polyneuropathy ( n = 1), and facial nerve palsy ( n = 1). Central nervous system involvement included aseptic meningitis, myelitis, and stroke (each n = 1). The number of ICI cycles prior to n‐irAE onset varied, with a median of 3 cycles (range 1–43). The median time from the last infusion to symptom onset was 7 days (range 2–24). n‐irAEs led to ICI discontinuation and/or immunomodulatory treatments in 9 patients. Clinical improvement was observed in 7 of 10 cases. No deaths were attributed to ICI‐related toxicity. Conclusion: Our findings indicate that severe n‐irAEs are rare. Nonetheless, clinicians should remain vigilant for delayed‐onset neurotoxicity, even after long treatment exposure. Most patients showed clinical improvement following ICI discontinuation and/or immunomodulatory treatments.
- 2 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70652
Open AccessSevere Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs). Here, we retrospectively characterized severe n‐irAEs in a monocentric cohort. Methods: We screened an in‐house registry of the Medical University of Vienna, Austria, including all patients treated with ICIs between 2007 and 2023. Patients who underwent a neurological evaluation were identified, and their medical records were reviewed. Cases with severe (i.e., grade ≥ 3) n‐irAEs were analyzed. We report clinical and demographic characteristics, neurological manifestations, treatment and outcomes. Results: Ten out of 2043 screened patients (i.e., 0.5%) developed severe n‐irAEs. In most cases ( n = 7), neurological manifestations involved the neuromuscular system and/or peripheral nerves, including myasthenia/myositis ( n = 5), polyneuropathy ( n = 1), and facial nerve palsy ( n = 1). Central nervous system involvement included aseptic meningitis, myelitis, and stroke (each n = 1). The number of ICI cycles prior to n‐irAE onset varied, with a median of 3 cycles (range 1–43). The median time from the last infusion to symptom onset was 7 days (range 2–24). n‐irAEs led to ICI discontinuation and/or immunomodulatory treatments in 9 patients. Clinical improvement was observed in 7 of 10 cases. No deaths were attributed to ICI‐related toxicity. Conclusion: Our findings indicate that severe n‐irAEs are rare. Nonetheless, clinicians should remain vigilant for delayed‐onset neurotoxicity, even after long treatment exposure. Most patients showed clinical improvement following ICI discontinuation and/or immunomodulatory treatments.
- Open Access
- 16 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 51-66
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)
We present a single-arm, phase II, neoadjuvant trial with the oncolytic virus talimogene laherparepvec (T-VEC) in 18 patients with difficult-to-resect cutaneous basal cell carcinomas. The primary end point, defined as the proportion of patients, who after six cycles of T-VEC (13 weeks), become resectable without the need for plastic reconstructive surgery, was already achieved after stage I (9 of 18 patients; 50.0%); thus the study was discontinued for early success. The objective response rate was 55.6% and the complete pathological response rate was 33.3%. Secondary end points included safety, relapse-free survival and overall survival, time to occurrence of new basal cell carcinomas and biological read outs. Only mild adverse events occurred. The 6-month relapse-free survival and overall survival rates were 100%. In two patients a new basal cell carcinoma was diagnosed. T-VEC led to a significant increase in cytotoxic T cells (P = 0.0092), B cells (P = 0.0004) and myeloid cells (P = 0.0042) and a decrease in regulatory T cells (P = 0.0290) within the tumor microenvironment. Together, neoadjuvant T-VEC represents a viable treatment option for patients with difficult-to-resect basal cell carcinomas (EudraCT no. 2018-002165-19).
- 16 January 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (1) , 51-66
Open AccessEfficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)
We present a single-arm, phase II, neoadjuvant trial with the oncolytic virus talimogene laherparepvec (T-VEC) in 18 patients with difficult-to-resect cutaneous basal cell carcinomas. The primary end point, defined as the proportion of patients, who after six cycles of T-VEC (13 weeks), become resectable without the need for plastic reconstructive surgery, was already achieved after stage I (9 of 18 patients; 50.0%); thus the study was discontinued for early success. The objective response rate was 55.6% and the complete pathological response rate was 33.3%. Secondary end points included safety, relapse-free survival and overall survival, time to occurrence of new basal cell carcinomas and biological read outs. Only mild adverse events occurred. The 6-month relapse-free survival and overall survival rates were 100%. In two patients a new basal cell carcinoma was diagnosed. T-VEC led to a significant increase in cytotoxic T cells (P = 0.0092), B cells (P = 0.0004) and myeloid cells (P = 0.0042) and a decrease in regulatory T cells (P = 0.0290) within the tumor microenvironment. Together, neoadjuvant T-VEC represents a viable treatment option for patients with difficult-to-resect basal cell carcinomas (EudraCT no. 2018-002165-19).
- Open Access
BRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis
The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection in BRAFi-associated skin carcinogenesis, however, is still inconclusive. Employing the Mus musculus papillomavirus 1 (MmuPV1) skin infection model, the impact of BRAFis and UVB exposure on papillomavirus induced skin tumorigenesis was investigated in immunocompetent FVB/NCrl mice. Systemic BRAF inhibition in combination with UVB light induced skin tumors in 62% of the MmuPV1-infected animals. In contrast, significantly fewer tumors were observed in the absence of either BRAF inhibition, UVB irradiation or virus infection, as demonstrated by lesional outgrowth in 20%, 5% and 0% of the mice, respectively. Combinatory exposure to BRAFis and UVB favored productive viral infection, which was shown by high numbers of MmuPV1 genome copies and E1^E4 spliced transcripts and an abundance of E6/E7 oncogene mRNA and viral capsid proteins. BRAF inhibition, but not viral infection or UVB light, activated ERK1/2, whereas γH2AX expression, inducible by UVB light, remained unaltered by BRAFis. These results provide experimental evidence that BRAF inhibition and UVB irradiation synergistically promote MmuPV1-induced skin tumor development in vivo. This indicates an alternative pathway by which papillomavirus skin infection may contribute to BRAFi-associated skin tumorigenesis.
Open AccessBRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis
The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection in BRAFi-associated skin carcinogenesis, however, is still inconclusive. Employing the Mus musculus papillomavirus 1 (MmuPV1) skin infection model, the impact of BRAFis and UVB exposure on papillomavirus induced skin tumorigenesis was investigated in immunocompetent FVB/NCrl mice. Systemic BRAF inhibition in combination with UVB light induced skin tumors in 62% of the MmuPV1-infected animals. In contrast, significantly fewer tumors were observed in the absence of either BRAF inhibition, UVB irradiation or virus infection, as demonstrated by lesional outgrowth in 20%, 5% and 0% of the mice, respectively. Combinatory exposure to BRAFis and UVB favored productive viral infection, which was shown by high numbers of MmuPV1 genome copies and E1^E4 spliced transcripts and an abundance of E6/E7 oncogene mRNA and viral capsid proteins. BRAF inhibition, but not viral infection or UVB light, activated ERK1/2, whereas γH2AX expression, inducible by UVB light, remained unaltered by BRAFis. These results provide experimental evidence that BRAF inhibition and UVB irradiation synergistically promote MmuPV1-induced skin tumor development in vivo. This indicates an alternative pathway by which papillomavirus skin infection may contribute to BRAFi-associated skin tumorigenesis.
- Open Access
- 5 June 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (8) , e202402671
Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with dabrafenib or encorafenib. Together, these findings provide insights into the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
- 5 June 2024
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 7 (8) , e202402671
Open AccessOff-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with dabrafenib or encorafenib. Together, these findings provide insights into the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
- Open Access
- 8 March 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (3) , 613-626
Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα
Introduction Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown. Methods In this study, we compared the composition of cutaneous, lesional and non-lesional immune cells and blood immune cells in ixekizumab- or adalimumab-treated patients with psoriasis. Results Our data reveal that both treatments efficiently downregulate T cells, macrophages and different subsets of dendritic cells (DCs) in lesional skin towards levels of healthy skin. In contrast to lesional skin, non-lesional areas in patients harbor only few or no detectable DCs compared to the skin of healthy subjects. Treatment with neither ixekizumab nor adalimumab reversed this DC imbalance in non-lesional skin of psoriatic patients. Conclusion Our study shows that anti-IL-17A and anti-TNFα therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
- 8 March 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (3) , 613-626
Open AccessRegulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα
Introduction Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic plaque psoriasis. The effects of these treatments on immune cell populations in the skin are largely unknown. Methods In this study, we compared the composition of cutaneous, lesional and non-lesional immune cells and blood immune cells in ixekizumab- or adalimumab-treated patients with psoriasis. Results Our data reveal that both treatments efficiently downregulate T cells, macrophages and different subsets of dendritic cells (DCs) in lesional skin towards levels of healthy skin. In contrast to lesional skin, non-lesional areas in patients harbor only few or no detectable DCs compared to the skin of healthy subjects. Treatment with neither ixekizumab nor adalimumab reversed this DC imbalance in non-lesional skin of psoriatic patients. Conclusion Our study shows that anti-IL-17A and anti-TNFα therapy rebalances the immune cell repertoire of lesional skin in psoriatic patients but fails to restore the disturbed immune cell repertoire in non-lesional skin.
- 21 January 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 199, 113561
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
- 21 January 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 199, 113561
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
- Open Access
Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. Blood vessels are in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that all clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with Vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with Dabrafenib or Encorafenib. Together, these findings provide insights on the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
Open AccessOff-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. Blood vessels are in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that all clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with Vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with Dabrafenib or Encorafenib. Together, these findings provide insights on the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
- Open Access
- 10 May 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (8) , 1606-1615
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune‐related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD‐1i and 50% of CTLA4i‐treated patients. Severe cutaneous irAE do not often occur but could be life‐threatening and may persist despite treatment discontinuation.Methods: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real‐world, phase IV, post‐marketing study using a follow‐up questionnaire.Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow‐up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug‐related eruptions and pigmentary diseases.Results: Inflammatory benign dermatoses (n = 63) represented the most common group of reactions (52.5%), followed by drug‐related eruptions (n = 24, 20%), pigmentary diseases (n = 23, 19.2%) and bullous diseases (n = 10, 8.3%). Grade II (n = 41, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis‐like rash, urticarial eruption and vitiligo. Grade III (n = 18, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (n = 2, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (n = 95, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time‐to‐onset of 208 days and some late‐onset events.Conclusion: Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I–II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late‐onset cutaneous irAE are not uncommon. A dermatological follow‐up helps mitigate the risk of life‐threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.
- 10 May 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (8) , 1606-1615
Open AccessCutaneous manifestations induced by check point inhibitors in 120 melanoma patients—The European MelSkinTox study
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune‐related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD‐1i and 50% of CTLA4i‐treated patients. Severe cutaneous irAE do not often occur but could be life‐threatening and may persist despite treatment discontinuation.Methods: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real‐world, phase IV, post‐marketing study using a follow‐up questionnaire.Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow‐up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug‐related eruptions and pigmentary diseases.Results: Inflammatory benign dermatoses (n = 63) represented the most common group of reactions (52.5%), followed by drug‐related eruptions (n = 24, 20%), pigmentary diseases (n = 23, 19.2%) and bullous diseases (n = 10, 8.3%). Grade II (n = 41, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis‐like rash, urticarial eruption and vitiligo. Grade III (n = 18, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (n = 2, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (n = 95, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time‐to‐onset of 208 days and some late‐onset events.Conclusion: Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I–II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late‐onset cutaneous irAE are not uncommon. A dermatological follow‐up helps mitigate the risk of life‐threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.
- Open Access
- 16 January 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (6) , 544-551
Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells
Introduction: The implications of infiltrative compared to non‐infiltrative growth of cutaneous basal cell carcinoma (BCC) on the tumor stroma and immune cell landscape are unknown. This is of clinical importance, because infiltrative BCCs, in contrast to other BCC subtypes, are more likely to relapse after surgery and radiotherapy.Materials and Methods: This descriptive cross‐sectional study analyzed 38 BCCs collected from 2018 to 2021. In the first cohort (n = 28), immune cells were characterized by immunohistochemistry and multiplex immunofluorescence staining for CD3, CD8, CD68, Foxp3, and α‐SMA protein expression. In the second cohort (n = 10) with matched characteristics (age, sex, location, and BCC subtype), inflammatory parameters, including TGF‐β1, TGF‐β2, ACTA2, IL‐10, IL‐12A, and Foxp3, were quantified via RT‐qPCR after isolating mRNA from BCC tissue samples and perilesional skin.Results: Infiltrative BCCs showed significantly increased levels of α‐SMA expression in fibroblasts (p = 0.0001) and higher levels of Foxp3+ (p = 0.0023) and CD3+ (p = 0.0443) T‐cells compared to non‐infiltrative BCCs. CD3+ (p = 0.0171) and regulatory T‐cells (p = 0.0026) were significantly increased in α‐SMA‐positive tumor stroma, whereas CD8+ T‐cells (p = 0.1329) and CD68+ myeloid cells (p = 0.2337) were not affected. TGF‐β1 and TGF‐β2 correlated significantly with ACTA2/α‐SMA mRNA expression (p = 0.020, p = 0.005).Conclusion: Infiltrative growth of BCCs shows a myofibroblastic stroma differentiation and is accompanied by an immunosuppressive tumor microenvironment.
- 16 January 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (6) , 544-551
Open AccessMyofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T‐cells
Introduction: The implications of infiltrative compared to non‐infiltrative growth of cutaneous basal cell carcinoma (BCC) on the tumor stroma and immune cell landscape are unknown. This is of clinical importance, because infiltrative BCCs, in contrast to other BCC subtypes, are more likely to relapse after surgery and radiotherapy.Materials and Methods: This descriptive cross‐sectional study analyzed 38 BCCs collected from 2018 to 2021. In the first cohort (n = 28), immune cells were characterized by immunohistochemistry and multiplex immunofluorescence staining for CD3, CD8, CD68, Foxp3, and α‐SMA protein expression. In the second cohort (n = 10) with matched characteristics (age, sex, location, and BCC subtype), inflammatory parameters, including TGF‐β1, TGF‐β2, ACTA2, IL‐10, IL‐12A, and Foxp3, were quantified via RT‐qPCR after isolating mRNA from BCC tissue samples and perilesional skin.Results: Infiltrative BCCs showed significantly increased levels of α‐SMA expression in fibroblasts (p = 0.0001) and higher levels of Foxp3+ (p = 0.0023) and CD3+ (p = 0.0443) T‐cells compared to non‐infiltrative BCCs. CD3+ (p = 0.0171) and regulatory T‐cells (p = 0.0026) were significantly increased in α‐SMA‐positive tumor stroma, whereas CD8+ T‐cells (p = 0.1329) and CD68+ myeloid cells (p = 0.2337) were not affected. TGF‐β1 and TGF‐β2 correlated significantly with ACTA2/α‐SMA mRNA expression (p = 0.020, p = 0.005).Conclusion: Infiltrative growth of BCCs shows a myofibroblastic stroma differentiation and is accompanied by an immunosuppressive tumor microenvironment.